Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Significant Increase in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 55,700 shares, an increase of 28.0% from the February 28th total of 43,500 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average daily volume of 28,800 shares, the short-interest ratio is presently 1.9 days.

Aprea Therapeutics Price Performance

APRE opened at $1.87 on Thursday. Aprea Therapeutics has a 12-month low of $1.85 and a 12-month high of $6.70. The stock has a market capitalization of $10.27 million, a PE ratio of -0.67 and a beta of 0.82. The firm’s fifty day moving average price is $2.91 and its 200 day moving average price is $3.21.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, equities research analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

APRE has been the topic of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 25th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Aprea Therapeutics during the fourth quarter worth $43,000. LPL Financial LLC bought a new position in shares of Aprea Therapeutics in the 4th quarter worth about $53,000. Landscape Capital Management L.L.C. acquired a new position in shares of Aprea Therapeutics in the 4th quarter valued at about $116,000. Finally, Stonepine Capital Management LLC raised its stake in Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after acquiring an additional 12,047 shares during the period. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.